A Phase I Open Label Safety, Pharmacokinetic and Pharmacodynamic Dose Escalation Study of SF1126, A PI3 Kinase (PI3K) Inhibitor, Given Twice Weekly By IV Infusion To Patients With Advanced or Metastatic Tumors.

Trial Profile

A Phase I Open Label Safety, Pharmacokinetic and Pharmacodynamic Dose Escalation Study of SF1126, A PI3 Kinase (PI3K) Inhibitor, Given Twice Weekly By IV Infusion To Patients With Advanced or Metastatic Tumors.

Completed
Phase of Trial: Phase I

Latest Information Update: 12 Jun 2013

At a glance

  • Drugs SF 1126 (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions
  • Most Recent Events

    • 12 Jun 2013 Additional lead trial centre added as reported by ClinicalTrials.gov record.
    • 01 Jun 2011 Results from this trial will be presented at the 47th Annual Meeting of the American Society of Clinical Oncology (ASCO), according to a Semafore Pharmaceuticals media release.
    • 01 Jun 2011 Status changed from recruiting to completed, based on information provided in a Semafore Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top